Related Experiment Video

Updated: Jul 26, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

1.1K

Erdafitinib's Road to Approval and Use in Urothelial Carcinoma

Kirollos Hanna

    Oncology (Williston Park, N.Y.)
    |June 21, 2023
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
    09:38

    Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

    Published on: June 26, 2019

    8.0K
    Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
    06:08

    Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

    Published on: June 2, 2023

    1.8K

    Related Experiment Videos

    Last Updated: Jul 26, 2025

    Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
    08:36

    Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

    Published on: April 7, 2023

    1.1K
    Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
    09:38

    Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

    Published on: June 26, 2019

    8.0K
    Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
    06:08

    Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

    Published on: June 2, 2023

    1.8K

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    7.7K
    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    7.7K

    Articles linked to this work by shared authors, journal, and citation graph.

    Physician-pharmacy integration in cancer care: pillars of medically integrated pharmacy.

    The American journal of managed care·2026

    AMCP Market Insights: Managed care approaches to bispecific antibodies with a focus on follicular lymphoma and diffuse large B-cell lymphoma.

    Journal of managed care & specialty pharmacy·2025

    Number needed to treat and associated cost analysis of zanubrutinib vs ibrutinib in chronic lymphocytic leukemia.

    Journal of managed care & specialty pharmacy·2025

    Impact of melphalan day -1 vs day -2 on outcomes after autologous stem cell transplant for multiple myeloma.

    Frontiers in immunology·2024

    2021-2022 Drug Updates in Solid Tumors.

    Journal of the advanced practitioner in oncology·2023

    2020-2021 Drug Updates in Hematologic Malignancies.

    Journal of the advanced practitioner in oncology·2022

    Advancing Multidisciplinary Care and Health Equity in Metastatic Breast Cancer.

    Oncology (Williston Park, N.Y.)·2026

    Homologous Recombination and Mismatch Repair Assessment in Men With Advanced Prostate Cancer: A Cross-Sectional Study From a Center in Mexico City.

    Oncology (Williston Park, N.Y.)·2026

    Access to Care and Drug Prices: Recent Department of Health and Human Services Guidance.

    Oncology (Williston Park, N.Y.)·2026

    Clinical Outcomes of Acute Pancreatitis in Patients With Multiple Myeloma.

    Oncology (Williston Park, N.Y.)·2026

    Primary Malignant Melanoma of the Colon: A Rare and Challenging Diagnosis.

    Oncology (Williston Park, N.Y.)·2026

    Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.

    Oncology (Williston Park, N.Y.)·2026

    Statement on MRLs for difluoroacetic acid (DFA).

    EFSA journal. European Food Safety Authority·2026

    Review of the existing maximum residue levels for clopyralid according to Article 12 of Regulation (EC) No 396/2005.

    EFSA journal. European Food Safety Authority·2026

    Ethical Considerations for Wastewater and Environmental Surveillance in Carceral Settings: Building a Framework to Guide Public Health Interventions.

    American journal of public health·2026

    Heavy Metal Concentration in Swiss Chard (Beta vulgaris ssp. cicla L.) Cultivated Along River Banks in Addis Ababa, Ethiopia.

    International journal of analytical chemistry·2026

    Prediction of Ki-67 expression in hepatocellular carcinoma: a dual-center study based on T2-weighted imaging habitat analysis.

    Radiology and oncology·2026

    Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin).

    Dermatology and therapy·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us